This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) first-quarter performance is likely to reflect rising global awareness of the company's real-time CGM.
Why Baxter (BAX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Baxter (BAX) Up 2.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Baxter (BAX) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Baxter (BAX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Here's Why You Should Hold Onto Baxter (BAX) Stock for Now
by Zacks Equity Research
Baxter (BAX) issues strong guidance for the first quarter of 2020.
Baxter (BAX) Q4 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Baxter's (BAX) fourth-quarter earnings benefit from higher revenues, solid segmental performance and growth in APAC.
Why Earnings Season Could Be Great for Baxter (BAX)
by Zacks Equity Research
Baxter (BAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Products Industry Outlook: Growth Prospects Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.
Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems (VEEV) fiscal fourth-quarter results are likely to reflect robust product portfolio and higher revenues.
Why Earnings Season Could Be Great for Baxter (BAX)
by Zacks Equity Research
Baxter (BAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.
What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.
Baxter's Latest Acquisition to Boost Advanced Surgery Arm
by Zacks Equity Research
Baxter's (BAX) Advanced Surgery arm boasts of a wide spectrum of products.
Baxter (BAX) and COSMED Receive FDA Clearance for Q-NRG+
by Zacks Equity Research
The latest FDA clearance is likely to boost Baxter's (BAX) Clinical Nutrition segment.
Medical Products' Jan 30 Earnings Roster: TMO, EW & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.
What's in Store for Varian Medical (VAR) in Q1 Earnings?
by Zacks Equity Research
Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.
PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.
What's in the Cards for Intuitive Surgical (ISRG) Q4 Earnings?
by Zacks Equity Research
Better-than-expected performance at Instruments & Accessories segment and da Vince procedure growth are likely to have benefited Intuitive Surgical's (ISRG) Q4 earnings.
Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.
Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.
Medical Products' Oct 24 Earnings Roster: BAX, CERN & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
What's in the Offing for Baxter's (BAX) Earnings in Q3?
by Zacks Equity Research
Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.